1. Neuronal Signaling
  2. Cholinesterase (ChE)
  3. Dihydrowithaferin A

Dihydrowithaferin A  (Synonyms: 2,3-Dihydrowithaferin A)

Cat. No.: HY-N5120 Purity: 99.57%
Handling Instructions Technical Support

Dihydrowithaferin A (2, 3-dihydrowithaferin A) is a withanolide isolated from Withania somnifera. Dihydrowithaferin A is active against acetylcholinesterase (AChE).

For research use only. We do not sell to patients.

Dihydrowithaferin A Chemical Structure

Dihydrowithaferin A Chemical Structure

CAS No. : 5589-41-3

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

View All Cholinesterase (ChE) Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dihydrowithaferin A (2, 3-dihydrowithaferin A) is a withanolide isolated from Withania somnifera. Dihydrowithaferin A is active against acetylcholinesterase (AChE)[1].

IC50 & Target

AChE

 

Cellular Effect
Cell Line Type Value Description References
A549 IC50
17.2 μM
Compound: 10
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 22705001]
A549 IC50
19.7 μM
Compound: 38
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
A549 IC50
33.5 μM
Compound: 38
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
A549 IC50
33.5 μM
Compound: 10
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
B16-F10 IC50
> 10 μM
Compound: 20
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay
Cytotoxicity against mouse B16F10 cells after 72 hrs by MTS assay
[PMID: 22098611]
C3H 10T1/2 IC50
> 25 μM
Compound: 4
Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA
Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA
[PMID: 26169123]
DU-145 IC50
> 25 μM
Compound: 4
Cytotoxicity against human DU145 cells after 24 hrs by FMCA
Cytotoxicity against human DU145 cells after 24 hrs by FMCA
[PMID: 26169123]
HaCaT IC50
14.8 μM
Compound: 4
Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay
Inhibition of hedgehog/GLI1-mediated transcriptional activity in human HaCaT cells after 12 hrs by luciferase assay
[PMID: 26169123]
HeLa IC50
19.3 μM
Compound: 10
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 22705001]
HeLa IC50
28.9 μM
Compound: 38
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
HeLa IC50
28.9 μM
Compound: 10
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
HeLa IC50
32.2 μM
Compound: 38
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
MCF7 IC50
> 25 μM
Compound: 4
Cytotoxicity against human MCF7 cells after 24 hrs by FMCA
Cytotoxicity against human MCF7 cells after 24 hrs by FMCA
[PMID: 26169123]
MCF7 IC50
12.2 μM
Compound: 38
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
MCF7 IC50
14.4 μM
Compound: 38
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
MCF7 IC50
14.4 μM
Compound: 10
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
MCF7 IC50
5.4 μM
Compound: 10
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 22705001]
NCI-H929 IC50
> 10 μM
Compound: 20
Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay
Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay
[PMID: 24625088]
PANC-1 IC50
> 25 μM
Compound: 4
Cytotoxicity against human PANC1 cells after 24 hrs by FMCA
Cytotoxicity against human PANC1 cells after 24 hrs by FMCA
[PMID: 26169123]
SK-MEL-28 IC50
> 10 μM
Compound: 20
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTS assay
[PMID: 22098611]
Vero IC50
15.5 μM
Compound: 38
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
Vero IC50
15.5 μM
Compound: 10
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 22705001]
Vero IC50
24.2 μM
Compound: 38
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay
[PMID: 28923386]
Vero IC50
9 μM
Compound: 10
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay
[PMID: 22705001]
Molecular Weight

472.61

Formula

C28H40O6

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@]12[C@@]3([C@H](CCC2=O)O)[C@@H](C[C@]4([H])[C@]1([H])CC[C@@]5(C)[C@@]4([H])CC[C@]5([H])[C@@H]([C@@](O6)([H])CC(C)=C(CO)C6=O)C)O3

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (105.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1159 mL 10.5795 mL 21.1591 mL
5 mM 0.4232 mL 2.1159 mL 4.2318 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (2.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.25 mg/mL (2.64 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1159 mL 10.5795 mL 21.1591 mL 52.8977 mL
5 mM 0.4232 mL 2.1159 mL 4.2318 mL 10.5795 mL
10 mM 0.2116 mL 1.0580 mL 2.1159 mL 5.2898 mL
15 mM 0.1411 mL 0.7053 mL 1.4106 mL 3.5265 mL
20 mM 0.1058 mL 0.5290 mL 1.0580 mL 2.6449 mL
25 mM 0.0846 mL 0.4232 mL 0.8464 mL 2.1159 mL
30 mM 0.0705 mL 0.3527 mL 0.7053 mL 1.7633 mL
40 mM 0.0529 mL 0.2645 mL 0.5290 mL 1.3224 mL
50 mM 0.0423 mL 0.2116 mL 0.4232 mL 1.0580 mL
60 mM 0.0353 mL 0.1763 mL 0.3527 mL 0.8816 mL
80 mM 0.0264 mL 0.1322 mL 0.2645 mL 0.6612 mL
100 mM 0.0212 mL 0.1058 mL 0.2116 mL 0.5290 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dihydrowithaferin A
Cat. No.:
HY-N5120
Quantity:
MCE Japan Authorized Agent: